Scalable Biotech Manufacturing Targets $14B Cell Therapy Market
Research forecasts the global cell‑therapy manufacturing market to exceed $7 billion in 2026 and reach $14 billion by 2035. The FDA has introduced new manufacturing flexibility to accelerate approval timelines for cell and gene therapies, addressing a capacity bottleneck that analysts expect to constrain biologics output through 2026. Avaí Bio, rebranded from Avant Technologies, and its joint‑venture partner Austrianova have completed master cell bank work for an alpha‑Klotho‑producing therapy, feeding into Austrianova’s Cell‑in‑a‑Box encapsulation platform. The partnership positions scalable GMP manufacturing as a near‑term value driver for developers seeking to capture the expanding market.
Mortality Trends in Gen X & Millennials
The video highlights a new longitudinal study that tracks cause‑of‑death data from 1979 through 2023, revealing that people born between 1970 and 1985 – the tail end of Generation X and the early Millennials – are experiencing higher mortality rates...
Are We Managing Women’s Health All Wrong?
The Longevity Technology Unlocked episode challenges the prevailing male‑centric approach to health by spotlighting women’s unique hormonal cycles, metabolic needs, and social biology. Hosts Dr. Nina Patrick, Dr. Laura Briden, and Dr. Molly Malof argue that conventional hormonal birth control...
Peptides Target “Undruggable” Diseases
Santa Cruz‑based company specializing in unnatural macrocyclic peptide therapeutics announced a $45 million Series B round and a $1.7 billion collaboration with Novartis. The partnership targets cardiovascular proteins that have eluded conventional small‑molecule and antibody approaches. The firm positions macrocyclic peptides between traditional small...
Focus on What Counts
The video "Focus on What Counts" outlines a practical framework for applying the 80/20 rule to personal and professional priorities, urging viewers to distill their objectives into a “focus five” each quarter. The speaker explains how to rank the five items,...
How Can You Turn Your Stress Into Advantage?
The Longevity Technology Unlocked episode tackles how stress can be reframed from a purely damaging force into a lever for vitality, drawing on neuroscience, eastern practices, and emerging wearables. Hosts Dr. Nina Patrick and Phil Newman interview Dr. Pedram Sojai,...
MBX Biosciences Reports 2025 Results and Advances Endocrine Pipeline
MBX Biosciences released its fourth‑quarter and full‑year 2025 results, reporting a net loss of $87 million, up from $61.9 million in 2024, as R&D spending climbed to $79.2 million. The company confirmed that its lead candidate canvuparatide for chronic hypoparathyroidism cleared a Phase 2...
Pretzel Therapeutics Presents PX578 Data Supporting POLG Disease Treatment
Pretzel Therapeutics presented preclinical data for its investigational small‑molecule PX578 at the 2026 MDA Clinical and Scientific Conference. The drug is designed to activate the mitochondrial DNA polymerase gamma (POLG) and restore mitochondrial DNA levels in patients with mitochondrial DNA...
Revive Expands Access to Physical Therapy via Orbit Telehealth Partnership
Revive Health announced a partnership with Orbit Telehealth to deliver virtual physical‑therapy services nationwide. The collaboration integrates Revive’s evidence‑based PT protocols with Orbit’s HIPAA‑compliant video platform, enabling clinicians to treat patients remotely. Launching in Q3 2024, the joint offering aims...
Clene Reports Full Year 2025 Results with ALS Drug Progress
Clene Inc reported FY2025 results, cutting its net loss to $26.2 million and holding $5.2 million in cash after a $28 million oversubscribed direct offering. Revenue stayed minimal at $200,000 as the company concentrates on its lead candidate, CNM‑Au8, which showed significant biomarker...
Serotonin Centers Unveils Medical Longevity Model for Fitness Industry
Serotonin Centers announced the Serotonin Partner Program, a medical longevity model for U.S. fitness facilities. The turnkey platform lets gyms add medically supervised services—weight loss, hormone optimization, peptide and NAD+ therapies, IV metabolic support—within dedicated longevity suites. Serotonin funds, staffs,...
Theriva Biologics Reports 2025 Results and Pipeline Progress
Theriva Biologics closed 2025 with $13.1 million in cash, rising to $15.2 million by February 2026, enough to fund operations into the first quarter of 2027. The company reported a net loss of $25.3 million, a modest improvement as R&D spend fell while...
MindImmune Lands ADDF Funding to Harness the Immune System Against Alzheimer’s
MindImmune Therapeutics secured a $5 million investment from the Alzheimer’s Drug Discovery Foundation to advance its lead candidate, MITI‑101, which targets peripheral immune pathways implicated in Alzheimer’s neuroinflammation. Unlike conventional amyloid‑ or tau‑focused approaches, the Cambridge‑based biotech aims to block CD11c‑positive...
The Mouth-Body Connection: Why Oral Health Matters for Longevity
The Longevity.Technology UNLOCKED episode highlights the mouth as a pivotal gateway to overall health, linking nasal breathing, oral microbiome, and dental habits to inflammation, sleep quality, and metabolic function. Clinicians Dr. Aoife Stack and Dr. James Goolnik argue that chronic...
Forever Young Explores the Longevity Revolution
The documentary "Forever Young" arrives as the longevity field moves from lab breakthroughs to public policy and everyday life. Featuring top geroscientists from the Buck Institute, Harvard and Stanford, the film argues that lifestyle and environment outweigh genetic destiny in...
How Your Mouth Shapes Your Longevity
In a recent conversation, Dr. Aoife Stack and Dr. James Goolnik argue that oral and airway health are foundational to longevity, influencing sleep, metabolism, immunity, and brain function. They explain how nasal breathing, tongue posture, and myofunctional therapy improve airway...
Longevity and Disease Insights Now in 20/20 BioLabs Blood Test
20/20 BioLabs has launched OneTest for Longevity, a lab‑developed blood test that combines inflammatory biomarkers, lifestyle data, and AI to deliver personalized aging and chronic disease risk insights. The platform leverages IBM's watsonx.ai and the University of South Carolina's Dietary...
Sleep Rhythms and Dementia Risk Link Emerges
Alzheimer’s disease now affects 55 million people worldwide, with 10 million new cases each year, prompting researchers to explore upstream triggers beyond genetics. Texas A&M scientists have shown that chronic circadian disruption in animal models drives microglia into a stress‑primed, inflammatory state,...
ARPA-H Funding, Brain Wearables, & Nanotech Biosensing | Longevity News Roundup — Week 10, 2026
The U.S. ARPA‑H agency announced a $144 million PROSPR program to accelerate human health‑span trials, awarding $30.8 million to Cambrian BioPharma for a next‑generation rapamycin analog and $22 million to Linnaeus Therapeutics for repurposed oncology drugs. Meanwhile, startups are pushing wearable and digital...
Is Neurodegeneration a Systemic Metabolic Condition?
British biotech Vesalic reports a breakthrough that links amyotrophic lateral sclerosis (ALS) to a systemic metabolic dysfunction detectable in blood extracellular vesicles (EVs). The company says the EVs carry a toxic lipid cargo that harms motor neurons, and its blood‑based...
🎙️ Lifestyle Medicine and Healthspan
Allen Law outlines lifestyle medicine’s six pillars—diet, exercise, stress management, restorative sleep, avoidance of harmful substances, and nurturing social connections. He argues that consistent daily habits across these areas can significantly boost healthspan, the period of life spent in good...
Designing Healthspan: Inside the Morrow Model
The episode features Allen Law and Dr. William Tan discussing Morrow’s preventive health platform that integrates diagnostics, AI coaching, and community to turn biomarker data into daily habits. They critique modern medicine’s reactive nature and outline six pillars of lifestyle...
🎙️ Nanoplastics in the Human Brain
Researchers published in the Journal of Clinical Investigation that nanoplastics can traverse the blood‑brain barrier and accumulate within human brain tissue. The study identified these ultra‑small particles, comparable in size to viruses, in both young and older individuals. Notably, brains...
🎙️ Targeting Inflammaging with AI
Scienta introduced EVA, an AI model designed to combat inflammaging. EVA integrates multi‑omic preclinical and clinical data to map inflammatory pathways linked to age‑related diseases. The platform proposes novel therapeutic targets and compounds aimed at restoring youthful immune signaling. The...
Nanoplastics, mRNA Therapy, & Drug Approvals | Longevity News Roundup — Week 9, 2026
Recent longevity news highlights nanoplastics in brains, a pioneering mRNA therapy, and regulatory shifts accelerating anti‑aging drug development. Researchers found ultra‑small plastic particles accumulating in Alzheimer‑affected brain tissue, independent of age. Klothea launched a phase 1b trial of AKL003 mRNA to...